MyKronoz Introduces ZePods Fashionable and Colorful True Wireless Earbuds, Together with a New Line of Affordable Smartwatches
26.2.2019 14:38:00 EET | Business Wire | Press release
Swiss wearable brand MyKronoz today announced ZePods, its first collection of true wireless earphones, unveiled at Mobile World Congress Barcelona 2019. Offering an impressive sound quality, up to 15 hours of playtime, stylish design with 6 vibrant colors and matching USB-C charging case, intuitive touch control to manage music, calls and voice commands thanks to its Bluetooth 5.0 technology - MyKronoz’s first true wireless earbuds will come in two versions with distinctive design and features:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190226005577/en/
ZePods - Wireless TWS earbuds (Photo: MyKronoz)
- ZePods, with a USB-C charging case boasting the familiar look of a sleek lighter. Available in April 2019 for a MSRP of 79,90€/$ only.
- ZePods+, with a Qi-certified wireless charging case whose shape has been greatly inspired by Swiss traditional pocket-watch. Available H2 2019 for a MSRP of 99,90€/$.
"Building on our Swiss DNA for design and our strong background in wearable technology, we believe that MyKronoz has a tremendous opportunity to seize in the flourishing market of wireless earbuds. The launch of ZePods appears as a natural and strategic evolution for our company to leverage expertise in developing affordable consumer-driven products and diversify to offer a full ecosystem." said Boris Brault, MyKronoz Founder and CEO.
In addition to ZePods, MyKronoz goes back to basics of affordable fashion wearables with a complete new line starting at 29.90 €/$, featuring activity tracker, smartwatches, sport smartwatches and hybrids to cater a large and diversified audience. Among the new collection, 4 products highlights:
- ZeTrack - a slim and full-featured HR activity tracker with color touchscreen. MSRP: 29.90€/$ - Launch date: end of March 2019.
- ZeNeo - a real powerful smartwatch with mic & speaker that looks like a sleek activity tracker. MSRP: 59.90€/$ - Launch date: end of April 2019.
- ZeRound3 Lite - the go-to smartwatch designed for your active lifestyle. MSRP: 79.90€/$ - Launch date: end of April 2019.
- ZeRound3 - the genuinely stylish connected smartwatch with AMOLED display. MSRP: 99.90€/$ - Launch date: end of March 2019.
The rest of the range includes ZeSport2, a multi-sport GPS smartwatch, already available at a MSRP of 149.90€/$. MyKronoz will continue to innovate in H2 2019 with ZePop - the hybrid smartwatch that blends fashion and tech. MSRP: 129,90€/$ as well as ZeTime2 - a stainless steel hybrid smartwatch with microphone, AMOLED display and real mechanical hands. MSRP: 199,90€/$.
ZePods, as well as the MyKronoz full new wearable collection will be on display and available for demos on the MWC 2019 show foor at the MyKronoz booth in the Congress Square (Booth #CS118) February 25-28th, 2019.
ABOUT MYKRONOZ:
MyKronoz is part of BOW Group, a global player in lifestyle consumer products, operating worldwide in the design and wearables markets with its 2 brands: MyKronoz and LEXON.
Since July 2015, BOW has opened up its capital to Next Stage AM, then, in 2017 to PM Equity Partner - the corporate venture fund of Philip Morris International. MyKronoz ZeTime has convinced over 40,000 backers in more than 100 countries and became the world's highest funded hybrid smartwatch with more than $8 million raised, as well as the largest crowdfunding campaign ever from a European company and the most backed product of 2017 on Kickstarter.
BOW Group has now more than 100 talents spread across four office locations: Paris, Geneva, Miami and Shenzhen.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190226005577/en/
Contact information
International media:
Annabel
Corlay
press@mykronoz.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TVS Motor Company Returns to EICMA With New Models for Europe26.10.2026 13:45:00 EET | Press release
TVS Motor Company (TVSM), a global leader in two- and three-wheeler manufacturing, returns to EICMA in Milan this November, one year after its debut at the world’s largest two-wheeler exhibition. The company will present new models for Europe at a press conference on Tuesday, 3 November at 10:00 CET. The TVS stand is in Hall 18, Stand I64. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026990290/en/ TVS Motor Company will present new models for Europe at a press conference on Tuesday, 3 November at 10:00 CET at EICMA this year. EICMA 2025 marked the beginning of TVS Motor's European growth journey. Since then, the company has focused on establishing the foundations for long-term success, building its dealer network, aftersales capabilities and customer support infrastructure across key markets. In Italy, its first European market, TVS now works with around 100 dealers. Retail sales in Italy are up 110% this year to Septem
Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function26.10.2026 13:00:00 EET | Press release
Merck, a leading science and technology company, today announced new two-year follow-up results from the Phase 3 MANEUVER study evaluating pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The study showed that among patients initially randomized to pimicotinib, improvements in symptoms and joint function were observed as early as Week 5, sustained through two years, and continued to improve over time. Tumor responses remained robust1 and durable,2 and the safety profile was consistent with previous analyses. The findings are being presented today in the Sarcoma poster session at the European Society for Medical Oncology (ESMO) Congress 2026 (Presentation # 3747P). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022786567/en/ David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck "For people living with TGCT, the impact of the disease is often felt through persis
WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 12:30:00 EET | Press release
WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural world, the collection introduces a newly developed system of WHOOP bands, Italian technical apparel, outerwear, and accessories designed to move between urban and outdoor settings. Performance extends be
Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 12:28:00 EET | Press release
Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums bleeding when brushing can happen to any of us. When they do, it shouldn't be ignored," said Eva Castro Perea, who holds a degree in dentistry
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom